Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins.
Altered geometry of the neuromuscular junction and a decreased number of acetylcholine receptors appear responsible for the defect of neuromuscular transmission in myasthenia gravis. We have used cultured rat myotubes as a model to study in vitro the potential role of myasthenic globulins in the pathological process. Acetylcholine receptor content was assayed by the extent of 125I-labeled alpha-bungarotoxin binding, and acetylcholine receptor function was assayed by the sensitivity to acetylcholine iontophoresis. The half-life of the acetylcholine receptor was 18.5 hr in the presence or absence of control sera. Myasthenic sera and globulins produced a gradual reduction in acetylcholine receptors, as assessed by biochemical and electrophysiological techniques. The half-life in the presence of myasthenic sera was 6 hr. The accelerated turnover was unaffected by puromycin but was slowed by lowered temperature (18-20 degrees), interference with energy metabolism (2,4-dinitrophenol), and interference with cytoskeletal structures (colchicine and cytochalasin B). We found no electrophysiological evidence to suggest globulin blockade of acetylcholine access to the acetylcholine receptor. Our observations suggest that circulating globulins in myasthenia gravis may contribute to the functional defects of neuromuscular transmission by accelerating the rate of internationalization and degradation of surface membrane acetylcholine receptors.
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D000937:Antigen-Antibody Reactions; D002038:Bungarotoxins / Q000378:metabolism; D002478:Cells, Cultured; D003078:Colchicine / Q000494:pharmacology; D003571:Cytochalasin B / Q000494:pharmacology; D004140:Dinitrophenols / Q000494:pharmacology; D007518:Isoantibodies; D008564:Membrane Potentials / Q000187:drug effects; D009132:Muscles / Q000276:immunology* / Q000378:metabolism; D009157:Myasthenia Gravis / Q000276:immunology*; D051381:Rats; D011950:Receptors, Cholinergic / Q000378:metabolism*; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism*; D013696:Temperature
D002038:Bungarotoxins; D004140:Dinitrophenols; D007518:Isoantibodies; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D003571:Cytochalasin B; D000109:Acetylcholine; D003078:Colchicine
J Clin Invest. 1976 Dec;58(6):1442-9
993353
Nature. 1976 Nov 4;264(5581):74-6
1004540
J Physiol. 1975 Nov;252(3):771-89
1206575
Eur J Immunol. 1972 Jun;2(3):203-12
4569167
Lancet. 1975 Mar 15;1(7907):607-9
47950
J Exp Med. 1973 Mar 1;137(3):675-89
4540168
J Cell Biol. 1975 May;65(2):335-58
236319
Ann N Y Acad Sci. 1976;274:319-36
183587
Exp Neurol. 1976 Jun;51(3):536-63
179836
Science. 1974 Oct 4;186(4158):55-7
4421998
Nature. 1974 Jul 5;250(461):54-6
4841158
Science. 1973 Oct 19;182(4109):293-5
4742736
Science. 1973 May 25;180(4088):871-2
4706680
Ann N Y Acad Sci. 1971 Sep 15;183:46-63
5287834
Ann N Y Acad Sci. 1976;274:60-79
1066997
Ann N Y Acad Sci. 1976;274:475-92
1066995
Ann N Y Acad Sci. 1976;274:275-82
1066989
Ann N Y Acad Sci. 1976;274:254-74
1066988
Proc Natl Acad Sci U S A. 1975 Nov;72(11):4430-4
1060123
Science. 1975 Oct 24;190(4212):397-9
1179220
N Engl J Med. 1975 Oct 9;293(15):760-1
1160955
Biochim Biophys Acta. 1975 May 30;393(1):66-77
1138925
Nature. 1975 Feb 20;253(5493):643-4
1113859
Exp Cell Res. 1975 Mar 1;91(1):125-42
1132413
Proc Natl Acad Sci U S A. 1968 Oct;61(2):477-83
5245982